Fortress Bio, Cyprium Therapeutics Update NDA For CUTX-101
01 Oct 2025 //
GLOBENEWSWIRE
Er-Kim, Sentynl Therapeutics Partner On Nulibry & Zokinvy
24 Sep 2025 //
GLOBENEWSWIRE
Sentynl Therapeutics: Clinical Evidence for Nulibry in Molybdenum
04 Apr 2025 //
BUSINESSWIRE
Sentynl`s CUTX-101 NDA Gets FDA Priority Review For Menkes Disease
06 Jan 2025 //
PR NEWSWIRE
Sentynl Therapeutics Receives Great Place To Work® Certification
03 Jun 2024 //
PR NEWSWIRE
Zydus unit acquires global rights to Eiger BioPharma’s Zokinvy
06 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Sentynl Acquires Zokinvy® For Progeria From Eiger Globally
03 May 2024 //
PR NEWSWIRE
UK MHRA approves Sentynl ’ Nulibry for injection a first therapy fo MoCD type A
18 Apr 2024 //
PHARMABIZ